Evidence map›Paper›PMID 42150334›Full record

ReviewAnais brasileiros de dermatologia

Psoriasis in skin of color: clinical presentation, diagnostic challenges, and therapeutic considerations.

Anderson Costa, Ricardo Romiti

Abstract readReview
In one paragraph

Review in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anderson CostaDepartment of Dermatology, Hospital Ipiranga, São Paulo, SP, Brazil.
Ricardo RomitiDepartment of Dermatology, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address: rromiti@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis in individuals with Skin of Color (SOC) shows distinctive clinical features and particularities that require careful consideration for accurate recognition and care. Erythema is often less apparent, and plaques may appear violaceous or dark brown. These features, together with limited discussion of these nuances in textbooks and articles, contribute to delayed diagnosis, greater reliance on skin biopsy, and reduced diagnostic accuracy. Although overall prevalence may be lower than in White populations, SOC patients frequently present with greater body-surface involvement, thicker scale, and a disproportionate impact on quality of life. Early, effective control is critical not only to limit systemic comorbidities and quality of life impairment but also to prevent post-inflammatory dyspigmentation, which can persist for years after clinical resolution and substantially affect psychosocial well-being. Despite major advances in psoriasis research, important gaps remain regarding genetic drivers, immunopathogenesis, and the comparative effectiveness and safety of therapies across diverse populations, gaps compounded by the persistent underrepresentation of SOC in clinical trials. This review synthesizes current evidence on epidemiology, clinical presentation, diagnostic pitfalls, pigmentary sequelae, psychosocial dimensions, and therapeutic options so as to support equitable, patient-centred outcomes for SOC patients living with psoriasis.

Indexed as

PsoriasisEthnic and Racial MinoritiesHumansQuality of LifeBiological productsEthnic groupsHealthcare disparitiesPsoriasisSkin pigmentation

Identifiers

PMID42150334
PMCPMC13202572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.